Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ABVX
$122.9695
$
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Next Earnings
2026-02-25
Beta
-0.42
Average Volume
Market Cap
Last Dividend
CIK
0001956827
ISIN
US00370M1036
CUSIP
00370M103
CEO
Marc de Garidel
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
69
IPO Date
2023-10-20
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 | Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 | GlobeNewsWire | 2026-02-21 06:00:00 |
| Alger Mid Cap Growth Fund Q4 2025 Portfolio Update | Class A shares of the Alger Mid Cap Growth Fund outperformed the Russell Midcap Growth Index during the fourth quarter of 2025. Cidara Therapeutics, Inc., Natera, Inc., and Abivax were among the top contributors to performance. Roblox Corp. Class A, e.l.f. Beauty, Inc., and Nebius Group were among the top detractors from performance. | Seeking Alpha | 2026-02-17 13:25:00 |
| Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. | Eli Lilly set the bar high, and it will be hard for other drugmakers to match its performance. Viking Therapeutics and Abivax are developing promising candidates. | The Motley Fool | 2026-02-10 20:11:00 |
| Better Long-Term Buy: This Emerging Player or the Industry Leader? | AbbVie is a well-established drugmaker with fast-growing immunology products and a solid dividend program. Abivax could challenge pharmaceutical giants like AbbVie in a niche of the immunology market. | The Motley Fool | 2026-01-30 15:30:00 |
| Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance | From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust. | Seeking Alpha | 2026-01-29 22:30:00 |
| Abivax CEO dismisses 'noise' around rumored Eli Lilly bid | Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly may take over his company, and said market speculation about an ongoing review by French authorities was inconsistent with how French foreign-investment oversight works. | Reuters | 2026-01-20 06:01:48 |
| Prediction: This Healthcare Stock Could Soar by 72% in 2026 | And the share price appreciation could happen pretty soon. | Fool - Investing News | 2026-01-19 15:45:00 |
| Nvidia, Eli Lilly Launch $1 Billion AI Lab To Build Meds | NVIDIA and Eli Lilly launch a $1 billion AI lab to speed drug discovery, improve manufacturing, and apply artificial intelligence across research, clinical trials, and supply chains over the next five years. | Benzinga | 2026-01-13 10:37:33 |
| First Look: Fed Probe, Bank Cap Shock, Gold Soars, Deals | Stock News DOJ subpoenas Fed chair spark backlash: Federal prosecutors served grand jury subpoenas to Jerome Powell over testimony on Fed HQ renovations, prompt | GuruFocus | 2026-01-13 07:38:00 |
| Abivax (NASDAQ:ABVX) Sees Unusually-High Trading Volume After Analyst Upgrade | Abivax SA Sponsored ADR (NASDAQ: ABVX - Get Free Report) shares saw unusually-high trading volume on Monday after Morgan Stanley raised their price target on the stock from $101.00 to $145.00. Morgan Stanley currently has an overweight rating on the stock. Approximately 2,646,946 shares traded hands during trading, an increase of 24% from the previous session's | Defense World | 2026-01-13 01:52:42 |
| Abivax: Don't Just Buy The Rumor, Buy The Fundamentals | Abivax (ABVX) remains a Buy, driven by obefazimod's strong UC data and significant multi-billion dollar market potential. ABVX is a credible M&A target, with Eli Lilly and other pharma giants rumored as potential acquirers, but fundamentals—not acquisition hopes—should drive investment decisions. Key 2026 catalysts include Phase 3 UC maintenance topline data, potential NDA/MAA filings, and Phase 2B Crohn's disease results. | Seeking Alpha | 2026-01-12 12:31:38 |
| France has had no request for investment approval in biotech Abivax - official | France's finance ministry has received no request seeking investment approval in Abivax and has had no contact with Eli Lilly , a ministry official said on Monday, following media reports that the U.S. pharma giant was still interested in buying the French biotech firm. | Reuters | 2026-01-12 09:49:38 |
| Abivax stock rockets 30% on Eli Lilly takeover speculation | Abivax stock (EPA: ABVX) surged roughly 30% in early Paris trading Monday after French media reported that US pharmaceutical giant Eli Lilly was preparing a €15 billion ($17.5 billion) acquisition offer for the French biotech. | Invezz | 2026-01-12 09:32:37 |
| Abivax Surges on Report Ely Lily is Preparing $17.5 Billion Bid | Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday. | WSJ | 2026-01-12 05:03:00 |
| Abivax shares soar 23% as media report reignites M&A chatter | Shares in Abivax soared 23%, exceeding 121 euros, on Monday after a media report said U.S. pharma giant Eli Lilly was still interested in buying the French biotech company. | Reuters | 2026-01-12 04:38:08 |
| Abivax Provides 2026 Corporate Outlook | Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD space ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found no new safety signals with over 80% of participants having completed the 44-week double blind maintenance trial ABTECT-UC Phase 3 maintenance topline results expected late Q2 2026, with a subsequent US regulatory filing planned for late 2026 ENHANCE-CD Phase 2b induction trial of obefazimod in moderate-to-severely active Crohn's disease (CD) ongoing; induction results expected late 2026 22 abstracts accepted for upcoming February 2026 European Crohn's and Colitis Organization (ECCO) conference including oral presentation of obefazimod impact on fibrosis in in-vitro and preclinical models Cash runway expected into Q4 2027, after full debt reimbursement in Q4 2025 PARIS, France – January 7, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced its 2026 corporate outlook, highlighting new market insights, progress in the ABTECT-UC and ENHANCE-CD trials, and advances in its therapeutic pipeline. Updates from the ABTECT Phase 3 maintenance trial evaluating obefazimod for the treatment of moderate-to-severely active UC reinforce the therapy's safety profile and inform potential future combination strategies. | GlobeNewsWire | 2026-01-07 16:05:00 |
| Abivax (NASDAQ:ABVX) Reaches New 12-Month High – What’s Next? | Abivax SA Sponsored ADR (NASDAQ: ABVX - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $139.62 and last traded at $138.72, with a volume of 4152856 shares changing hands. The stock had previously closed at $114.94. Analyst Ratings Changes Several brokerages recently commented on | Defense World | 2025-12-25 04:37:10 |
| Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy | Abivax surged 1,470% YTD, driven by Obefazimod's clinical progress and takeover speculation, but I rate it Hold due to valuation risk. Obefazimod, a first-in-class oral therapy for ulcerative colitis, met key Phase 3 endpoints, with pivotal maintenance data expected mid-2026. ABVX boasts €589.7 million in cash, supporting operations through Q4 2027, despite high R&D-driven losses and a €15.3 million monthly cash burn. | Seeking Alpha | 2025-12-23 06:41:51 |
| Why Abivax Stock Was on Fire Today | New speculation arose about a potential buyout from a very deep-pocketed strategic investor. These first started to swirl in mid-December. | The Motley Fool | 2025-12-22 19:09:18 |
| Abivax to be Added to Nasdaq Biotechnology Index | Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. Didier Blondel, Chief Financial Officer of Abivax commented: “Our inclusion in the Nasdaq Biotechnology Index marks a significant milestone for Abivax. | GlobeNewsWire | 2025-12-18 16:05:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 6-K | 2026-02-23 | 2026-02-23 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13D/A | 2026-01-14 | 2026-01-14 | View Filing |
| 6-K | 2025-12-15 | 2025-12-15 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13D/A | 2025-10-30 | 2025-10-30 | View Filing |
| 6-K | 2025-09-08 | 2025-09-08 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13D/A | 2025-07-31 | 2025-07-31 | View Filing |
| 424B5 | 2025-07-24 | 2025-07-24 | View Filing |
| 6-K | 2025-07-24 | 2025-07-24 | View Filing |
| FWP | 2025-07-24 | 2025-07-24 | View Filing |
| FWP | 2025-07-23 | 2025-07-23 | View Filing |
| 424B5 | 2025-07-23 | 2025-07-23 | View Filing |
| F-3ASR | 2025-07-23 | 2025-07-23 | View Filing |
| 6-K | 2025-07-22 | 2025-07-22 | View Filing |
| 6-K | 2025-06-11 | 2025-06-11 | View Filing |
| 6-K | 2025-06-02 | 2025-06-02 | View Filing |
| 6-K | 2025-04-29 | 2025-04-29 | View Filing |
| 6-K | 2025-04-22 | 2025-04-22 | View Filing |
| SC 13G | 2025-04-11 | 2025-04-11 | View Filing |
| S-8 | 2025-03-24 | 2025-03-24 | View Filing |
| 20-F | 2025-03-24 | 2025-03-24 | View Filing |
| 6-K | 2025-03-24 | 2025-03-24 | View Filing |
| SC 13D/A | 2025-02-14 | 2025-02-14 | View Filing |
| 6-K | 2025-01-10 | 2025-01-10 | View Filing |
| 6-K | 2024-12-23 | 2024-12-23 | View Filing |
| EFFECT | 2024-11-27 | 2024-11-27 | View Filing |
| 6-K | 2024-11-19 | 2024-11-19 | View Filing |
| F-3 | 2024-11-19 | 2024-11-19 | View Filing |
| 6-K | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 6-K | 2024-10-03 | 2024-10-03 | View Filing |
| 6-K | 2024-10-03 | 2024-10-03 | View Filing |
| 6-K | 2024-09-26 | 2024-09-26 | View Filing |
| 6-K | 2024-09-25 | 2024-09-25 | View Filing |
| 6-K | 2024-09-09 | 2024-09-09 | View Filing |
| 6-K | 2024-09-09 | 2024-09-09 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Larry Williams PercentR Strategy | 41.03% | 0.99 | 260 | 0.04 | 0.12 | 28.72 |
| Volume Weighted Momentum Strategy | 32.13% | 1.15 | 16 | 0.05 | 0.19 | 19.82 |
| Triple MA | 19.48% | 1 | 719 | 0.01 | 0.06 | 7.17 |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxxx | x | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | x |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |